Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs

Annals of Oncology

Volumn 9, Issue 8, 1998, Pages 893-899

  Fuchs, N ^a   Bielack, S S ^a,b   Epler, D ^a   Bieling, P ^a   Delling, G ^b   Korholz D ^c   Graf, N ^d   Heise, U ^e   Jurgens H ^f   Kotz, R ^g   Salzer Kuntschik, M ^h   Weinel, P ⁱ   Werner, M ^b   Winkler, K ^a  

^a Kinderklinik   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e Orthopadische Gemeinschaftspraxis P   (Germany)

^f UNIVERSITY OF MÜNSTER   (Germany)

^g University of Vienna   (Austria)

^h Inst fur Klin Pathol der Univ

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chemotherapy; Cisplatin; Ifosfamide; Intraarterial therapy; Osteosarcoma

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE;

ADULT; ARTICLE; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LIMB SALVAGE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OSTEOSARCOMA; OTOTOXICITY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 7344229308     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008391103132     Document Type: Article

References (43)

1. Link MP, Goorin MA, Miser AW et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314: 1600-6.
2. Humphrey GB, Koops HS, Molenaar WM et al. Osteosarcoma in Adolescents and Young Adults. Boston: Kluwer Academic Publishers 1993.
3. Rosen G, Marcove RC, Caparros B et al. Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43: 1221-30.
4. Winkler K, Beron G, Kotz R et al. Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a cooperative German/Austrian study. J Clin Oncol 1984; 2: 617-23
5. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: A critical review. J Clin Oncol 1994; 12: 423-31.
6. Rosen G, Caparros B, Huvos AG et al. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49: 1221-39.
7. Winkler K, Beron G, Delling G et al. Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trial (COSS 82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6: 329-37.
8. Picci P, Sangiorgi L, Rougraff BT et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994; 12; 2699-705.
9. Bielack SS, Kempf-Bielack B, Winkler K. Osteosarcoma: Relationship of response to preoperative chemotherapy and type of surgery to local recurrence. J Clin Oncol 1996; 15: 683 (Letter).
10. Winkler K, Bielack S, Delling G et al. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin. high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (Study COSS 86). Cancer 1990; 66: 1703-10.
11. Salzer-Kuntschik M, Brand G, Delling G. Bestimmung des morphologischen Regressionsgrades nach Chemotherapie bei malignen Knochentumoren. Pathologie 1983; 4: 135-41.
12. Delling G, Zach W, Alm J. Quantitative Grundsubstanzbestimmung in Osteosarkomen und ihre Bedeutung für das Ansprechen auf eine Polychemotherapie. Verh Dtsch Ges Path 1985; 69: 605 (Abstr).
13. Bielack S, Knop J, Delling G et al. Scintigraphic follow-up of osteosarcoma during neoadjuvant chemotherapy. Results of the cooperative osteosarcoma study of the Society for Pediatric Oncology. Nucl Med 1988; 27: 237-41.
14. Knop J, Delling G, Salzer-Kuntschik M et al. Nuklearmedizinische Vorhersage des histologischen Tumoransprechens beim Osteosarkom. Klin Pädiatr 1989; 201: 285-92.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
16. Mantel M. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.
17. Cortes EP, Holland JF, Wang JJ, Sinks LF. Doxorubicin in disseminated osteosarcoma. JAMA 1972; 221: 1132-8.
18. Cortes EP, Holland JF, Wang JJ et al. Amputation and adriamycin in primary osteosarcoma. N Engl J Med 1974; 291: 998-1000.
19. Jaffe N, Frei III E, Traggis D et al. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med 1974; 291: 994-7.
20. Baum ES, Gaynon P, Greenberg L et al. Phase II study of cis-dichlorodiammineplatinum(II) in childhood osteosarcoma: Children's Cancer Study Group report. Cancer Treat Rep 1979; 63: 1621-7.
21. Rosen G, Nirenberg A, Caparros B et al. Osteosarcoma: Eighty percent, three year, disease free survival with combination chemotherapy (T7). Natl Cancer Inst Monogr 1981; 56: 213-20.
22. Pratt CB, Epelman S, Jaffe N. Bleomycin, cyclophosphamide, and dactinomycin in metastatic osteosarcoma: Lack of tumor regression in previously treated patients. Cancer Treat Rep 1987; 71: 421-3.
23. Kaatsch P, Kaletsch U, Michaelis J. Jahresbericht 1994 des Kinderkrebsregisters Mainz. Mainz: Johannes-Gutenberg-Universität, Institut für Medizinische Statistik und Information 1993.
24. Bramwell VH, Burgers M, Sneath R et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: The first study of the European Osteosarcoma Intergroup. J Clin Oncol 1992; 10: 1579-91.
25. Solheim OP, Saeter G, Elomaa I et al. The treatment of osteosarcoma: Present trends. The Scandinavian Sarcoma Group experience. Ann Oncol 1992; 3: 7-11.
26. Provisor AJ, Ettinger LJ, Nachman JB et al. Treatment of non-metastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group. J Clin Oncol 1997; 15: 79-84.
27. Brade WP, Herdrich K, Varini M. Ifosfamide: Pharmacology, safety, and therapeutic potential. Cancer Treat Rev 1985; 12: 1-47.
28. Bowman LC, Meyer WH, Douglass EC et al. Activity of ifosfamide in metastatic and unresectable osteosarcoma. Proc Am Soc Clin Oncol 1987; 6: 214 (Abstr).
29. Pratt CB, Horowitz ME, Meyer WH et al. Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep 1987; 71: 131-5.
30. Meyers PA. Randomized study of incorporating IFF into neoadjuvant and adjuvant DOX/CDDP/MTX chemotherapy in newly diagnosed, resectable osteogenic sarcoma. Childrens Cancer Group study CCG-7921 1993.
31. Rehan N, Bieling P, Winkler Pet al. The prognostic significance of tumor volume in osteosarcoma with neoadjuvant chemotherapy. Klin Pädiatr 1993; 205: 200-9.
32. Bieling P, Rehan N, Winkler P et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996; 14: 848-58.
33. Jaffe N, Knapp J, Chuang VP et al. Osteosarcoma: Intra-arterial treatment of the primary tumor with cis-diammine-dichloroplatinum II (CDP). Angiographic, pathologic, and pharmacologic studies. Cancer 1983; 51: 402-7.
34. Bielack S, Erttmann R, Looft G et al. Platinum disposition after intraarterial and intravenous infusion of cisplatinum for osteosarcoma. Cancer Chemother Pharmacol 19889; 24: 376-80.
35. Vermorken JB, Kaptlijn TS, Hart AAM. Ototoxicity of cis-diamminedichlorplatinum (II): Influence of dose, schedule, and mode of administration. Eur J Cancer Clin Oncol 1983; 19: 53-8.
36. McHaney V, Kovnar E, Meyer W et al. Effects of radiation therapy and chemotherapy on hearing. In Green DM, dAngio GJ (eds): Late Effects of Treatment for Childhood Cancer. New York: Wiley-Liss 1992; 7-10.
37. Prasad VK, Lewis IJ. Aparicio SR et al. Progressive glomerular toxicity of ifosfamide in children. Med Pediatr Oncol 1996; 27: 149-55.
38. Rossi R, Rath R, Ullrich K et al. Ifosfamid-induzierte Nephrotoxizität. Monatsschr Kinderheilkd 1993; 141: 594-601.
39. Rossi R, Gödde A, Kleinebrand A et al. Unilateral nephrectomy and cisplatin as risk-factors for ifosfamide-induced nephrotoxicity. Analysis of 120 patients. J Clin Oncol 1994; 12: 159-65.
40. Skinner R, Sharkey IM, Pearson ADJ et al. Ifosfamide, mesna and nephrotoxicity in children. J Clin Oncol 1993; 11: 173-90.
41. Geidel S, Garn M, Grävinghoff L et al. Cardiomyopathy after treatment for osteosarcoma: A contribution to the cardiotoxicity of adriamycin. Klin Pädiatr 1991; 203: 257-61.
42. Steinherz LJ, Steinherz PG, Tan CTC et al. Cardiotoxicity 4-20 years after completing anthracycline therapy. JAMA 1991; 266: 1672-7.
43. Lipshultz SE, Colan SD, Gelber RD et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-15.